Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia

Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that ha s recently become available for use in patients with relapsing or refractor y acute myeloid leukemia. Reversible hepatotoxicity is common after adminis tration. We describe the first report of hepatic veno-occlusive disease (HV OD) developing after Mylotarg infusion in a patient who underwent hematopoi etic stem cell transplantation 8 months earlier. Certain antineoplastic age nts have been implicated as a cause of HVOD, but the disease is most common ly seen within 30 days after hematopoietic stem cell transplantation. The p ossible association between Mylotarg infusion and HVOD is discussed.